

28th April, 2021

To, Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.
Ref.: Scrip Code No. : 540701	Ref. : (i) Symbol – DCAL (ii) Series – EQ

Sub.: Announcement: Company’s wholly-owned subsidiary viz. CARBOGEN AMCIS AG has entered into a joint funding agreement with a long-standing Japan based customer to build a site extension at the Bubendorf site in Switzerland

Dear Sir,


Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that Company’s wholly owned subsidiary namely CARBOGEN AMCIS AG., Switzerland has entered into a co-investment agreement of more than CHF 15 million with a Japan based key client to build a site extension at its Bubendorf site in Switzerland.

In this regard, please find enclosed herewith Press Release on the captioned subject.

Kindly take the same on your record.

Thanking You,

Yours faithfully,
For, Dishman Carbogen Amcis Limited



Shrima Dave
Company Secretary

Encl.: As above

Dishman Carbogen Amcis Limited

Regd. Off.: DISHMAN CORPORATE HOUSE
Iscon-Bopal Road, Ambli, Ahmedabad-380 058, Gujarat, India.
Phone : +91 (0) 2717 420102 / 2717 420124

E-mail : dc@dishmangroup.com
Website : www.dishmangroup.com

Government Recognised Export House
CIN No. : L74900GJ2007PLC051338

PRESS RELEASE

DISHMAN CARBOGEN AMCIS announces that its subsidiary, CARBOGEN AMCIS AG has entered into a co-investment agreement of more than CHF 15 million with a key client to expand Swiss site

Ahmedabad, India (28-04-2021) — The company's subsidiary, Carbogen Amcis AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today a joint funding agreement with a long-standing Japan based customer to build a site extension at the Bubendorf site in Switzerland.

The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will incorporate a new production line comprising of two 850 L reactors and one agitated filter drier. The facility is designed for highly potent manufacturing up to category 4 (OEL of 1 µg/m³ and lower).

"We are grateful for the trust our customer has placed in us by deciding to support the Bubendorf site extension. Their investment will enable the creation of a state-of-the art facility that will benefit them directly," said Pascal Villemagne, VP sales and Marketing, CARBOGEN AMCIS. "This joint investment cements our working relationship over the long term and lays the foundation for a promising future."

CARBOGEN AMCIS will produce exclusively for the signatory customer a complex highly potent drug component for a commercial antibody-drug-conjugate API.

"The production of this intermediate involves five Dishman Carbogen Amcis facilities around the world: three sites in Switzerland (Bubendorf, Hunzenschwil and Aarau), one in the UK (Manchester) and one in China (Shanghai). The highly potent production element will take place in Bubendorf, in the new building extension." commented Mark Griffiths, Director, Dishman Carbogen Amcis Limited. "We are thrilled and honoured to collaborate with our customer on this project to treat patients of need and also proud to demonstrate our ability to integrate our global supply chain network."

Currently, the planning phase for the building extension is underway and the Company expects to commence operations in autumn 2022.

###

CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Carbogen Amcis Limited., Ahmedabad, India.

Dishman Carbogen Amcis Limited (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis Group improves its customers' businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.